The Tumor Microenvironment in Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The tumor microenvironment (TME) of NSCLC is heterogeneous with variable blood flow though leaky immature vessels, resulting in regions of acidosis and hypoxia. Hypoxia has been documented in NSCLC directly by polarographic needle electrodes and indirectly by assessing tissue and plasma hypoxia markers. In general, elevated expression of these markers portends poorer outcomes in NSCLC. Impaired vascularity and hypoxia can lead to increased metastasis and treatment resistance. Compounds that directly target hypoxic cells such as tirapazamine have been tested in clinical trials for NSCLC with mixed results. Pre-clinical data, however, suggest other ways of exploiting the abnormal TME in NSCLC for therapeutic gain. Inhibition of HIF-1α or VEGF may increase local control after radiation. Inhibitors of the EGFR/PI3K/Akt pathway such as erlotinib or PI-103 may “normalize” tumor vessels, allowing for increased chemotherapy delivery or improved oxygenation and radiation response. In order to select patients who may respond to these therapies and to evaluate the effects of these agents, a non-invasive means of imaging the TME is critical. Presently, there are several promising modalities to image hypoxia and the tumor vasculature; these include dynamic perfusion imaging and positron emission tomography (PET) scanning with radiolabled nitroimidazoles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lysyl oxidase is essential for hypoxia-induced metastasis
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006) · Nature · doi:10.1038/nature04695 · Cited by 1,309
Self-citationRetractedNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684 · cited 1×
“These approaches are (1) measurement of partial oxygen pressure (pO2) with needle electrodes, (2) detection of hypoxia-induced proteins in tumor or blood, (3) and imaging hypoxia and tumor vasculature.”
MethodHIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
HIF-1 as a target for drug development
Giaccia, A., Siim, B. G., & Johnson, R. S. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1199 · Cited by 631
Giatromanolaki, A., Koukourakis, M. I., Sivridis, E., Turley, H., Talks, K., Pezzella, F., Gatter, K. C., & Harris, A. L. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2018 · Cited by 478
Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity
Moeller, B. J., Dreher, M. R., Rabbani, Z. N., Schroeder, T., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.016 · Cited by 374
Swinson, D. E. B., Jones, J. L., Cox, G., Richardson, D., Harris, A. L., & O'Byrne, K. J. (2004) · International Journal of Cancer · doi:10.1002/ijc.20052
Cited by
Lung cancer: Biology and treatment options
Lemjabbar-Alaoui, H., Hassan, O. U., Yang, Y.-W., & Buchanan, P. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,014
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Huang, L., & Fu, L. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.001 · Cited by 585
Travis, W. D., Dacic, S., Wistuba, I., Sholl, L., Adusumilli, P., Bubendorf, L., Bunn, P., Cascone, T., Chaft, J., Chen, G., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.005 · Cited by 465
Airway microbiota is associated with upregulation of the PI3K pathway in lung cancer
Tsay, J.-C. J., Wu, B. G., Badri, M. H., Clemente, J. C., Shen, N., Meyn, P., Li, Y., Yie, T.-A., Lhakhang, T., Olsen, E., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201710-2118oc · Cited by 448
Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin, S., Nehoff, H., & Greish, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.013 · Cited by 309
William, W. N., Pataer, A., Kalhor, N., Correa, A. M., Rice, D. C., Wistuba, I. I., Heymach, J., Lee, J. J., Kim, E. S., Munden, R., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182774108 · Cited by 138
PET in the management of locally advanced and metastatic NSCLC
Grootjans, W., de Geus-Oei, L.-F., Troost, E. G. C., Visser, E. P., Oyen, W. J. G., & Bussink, J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.75 · Cited by 97
Metadata
- Authors
- Graves, E. E., Maity, A., & Le, Q.-T.
- Venue
- Seminars in Radiation Oncology
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 20
- Issue
- 3
- Pages
- 156-163
- ISSN
- 1053-4296 (ISSN-L)
- OpenAlex
- W2150499465
- Cited by
- 138
- References
- 10
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.